
## **Trustees' Annual Report for the period** 

**From: 01 Dec 2024** 

**Period end date: 30 Nov 2025** 

**Charity name: British Society of Pharmacy Sleep Services (BSPSS)** 

**Charity registration number: 1198553** 

## **Objectives and Activities** 

||||
|---|---|---|
||**SORP**<br>**reference**||
||Para 1.17|A.<br>The advancement of health by raising awareness of<br>symptoms and the treatments available for those<br>sufering from sleep disorders.<br>B.<br>To advance the educaton of the public in general,<br>and partcularly amongst community pharmacists,<br>on the subject of sleep disorders.<br>C.<br>We provide essental informaton to pharmacists to<br>improve patent access to evidence-based sleep<br>informaton at the earliest possible stage and raise<br>awareness of symptoms and the treatments<br>available for those sufering from sleep disorders.<br>D.<br>We engage in research that accelerates access to<br>evidence-based help for sleep disorders.<br>E.<br>We do this to advance health and save lives of<br>those directly and indirectly impacted by sleep<br>disorders.|
|**Summary of the purposes**<br>**of the charity as set out in**<br>**its governing document**|||
||Para 1.17<br>and 1.19|Free online sleep educaton for community pharmacists;<br>sleep conditon factsheets; the fnd a sleep trained<br>pharmacist directory; supply of Sunrise and Zoll Itamar<br>home sleep apnoea test devices to a community pharmacy;<br>sleep workshops for MPharm students at King’s College<br>London.|
|**Summary of the main**<br>**actvites in relaton to**<br>**those purposes for the**<br>**public beneft, in partcular,**<br>**the actvites, projects or**<br>**services identfed in the**<br>**accounts.**|||





||Para 1.18|The trustees confrm that they have had regard to the<br>guidance issued by the Charity Commission on public<br>beneft.|
|---|---|---|
|**Statement confrming**<br>**whether the trustees have**<br>**had regard to the guidance**<br>**issued by the Charity**<br>**Commission on public**<br>**beneft**|||
|**Additonal informaton(optonal)**|||
||||
||**SORP**<br>**reference**||
||Para 1.38|We are not a grant-making charity.|
|**Policy on grant making**|||
||Para 1.38|We have neither the funds for such an investment nor the<br>intenton to create a relevant policy.|
|**Policy on social investment**<br>**including programme**<br>**related investment**|||
||Para 1.38|Our existence and day-to-day actvites are entrely reliant<br>on the goodwill and eforts of the trustees and our<br>volunteer CEO.|
|**Contributon made by**<br>**volunteers**|||
|||Volunteer design and marketng expertse freely given.|
|**Other**|||



## **Achievements and Performance** 

||||
|---|---|---|
||**SORP**<br>**reference**||
||Para 1.20|Research activity during the period included:<br>A scoping review of the evidence base for community<br>pharmacy sleep services.<br>An e-Delphi consensus study on professional standards<br>for community pharmacy sleep services.|
|**Summary of the main**<br>**achievements of the**<br>**charity, identfying the**<br>**diference the charity’s**<br>**work has made to the**<br>**circumstances of its**<br>**benefciaries and any**<br>**wider benefts to society as**<br>**a whole.**|||



**Additional information (optional)** 

**SORP reference** 



||Para 1.41|Scoping review anticipated to be submitted in the Autumn<br>of 2026.<br>We were paid by King’s College London for the delivery<br>of the four sleep workshops (received in Mar 2026).|
|---|---|---|
|**Achievements against**<br>**objectves set**|||
||Para 1.41|Receipts fell from £4,722 in the previous year to £1,326, a<br>reducton of approximately 72 per cent.|
|**Performance**<br>**of**<br>**fundraising actvites**<br>**against objectves set**|||
||||
||**SORP**<br>**reference**||
|||Declining income is of concern and raises the queston of<br>ongoing viability.<br>Our sleep workshops at King’s College London were<br>cancelled on cost grounds (the educaton sector is<br>contractng).|
||||
||Para 1.41|We do not currently make fnancial investments.|
|**Investment performance**<br>**against objectves**|||
||||
|**Other**|||
|**Financial Review**|||
||||
||||
||**SORP**<br>**reference**||
||Para 1.21|During the fnancial year (1 December 2024 to 30<br>November 2025) we received £1,326 and spent £1,775, a<br>defcit of £449. Cash funds carried forward at 30<br>November 2025 were £524, compared with £973 brought<br>forward at 1 December 2024.<br>This is the second consecutve year in which expenditure<br>exceeded income. In the year ended 30 November 2024<br>the charity received £4,722 and spent £5,368, a defcit of<br>£646.|
|**Review of the charity’s**<br>**fnancial positon at the**<br>**end of the period**|||
||Para 1.22|The trustees have not adopted a formal reserves policy<br>during the period and have since resolved to do so.|
|**Statement explaining the**<br>**policy for holding reserves**<br>**statng why they are held**|||





||Para 1.22|£524 at 30 November 2025, all unrestricted.|
|---|---|---|
|**Amount of reserves held**|||
||Para 1.22|Not applicable. The charity held reserves of £524 at the<br>period end.|
|**Reasons for holding zero**<br>**reserves**|||
||Para 1.24|None.|
|**Details of fund materially in**<br>**defcit**|||
||Para 1.23|Cash funds stood at £524 at 30 November 2025 and had<br>fallen to £145 by 31 December 2025.|
|**Explanaton of any**<br>**uncertaintes about the**<br>**charity contnuing as a**<br>**going concern**|||
|**Additonal informaton(optonal)**|||
||||
||**SORP**<br>**reference**||
||Para 1.47|Two sources provided 96 percent of the charity’s receipts<br>during the period.<br>Sefam Medical UK Ltd and Zoll Itamar|
|**The charity’s principal**<br>**sources of funds (including**<br>**any fundraising)**|||
||Para 1.46|Not currently applicable.|
|**Investment policy and**<br>**objectves including any**<br>**social investment policy**<br>**adopted**|||
||Para 1.46|We have limited funds, which restricts our choices.<br>While we cannot pay our CEO, this presents us with tme<br>limitatons.|
|**A descripton of the**<br>**principal risks facing the**<br>**charity**|||



**Structure, Governance and Management** 

**Description of charity’s trusts:** 

**SORP reference** Para 1.25 CIO by Foundation. **Type of governing document (trust deed, royal charter)** 



||Para 1.25|Charitable Incorporated Organisaton by foundaton.|
|---|---|---|
|**How is the charity**<br>**consttuted? (e.g.**<br>**unincorporated**<br>**associaton, CIO)**|||
||Para 1.25|Trustees are selected by majority board decision.<br>The trustees check that candidates have not been<br>disqualifed from actng as trustees, and candidates are<br>asked to confrm in writng that this is the case.<br>Candidates are asked to consider and declare any existng<br>or potental conficts of interest.<br>If the charity works with children or adults at risk, the<br>trustees seek any appropriate checks from the Disclosure<br>and Barring Service.|
|**Trustee selecton methods**<br>**including details of any**<br>**consttutonal provisions**|||
||||
||**SORP**<br>**reference**||
|||In the light of the checks and declaratons, the trustees<br>decide to go ahead and formalise the appointment of new<br>trustees.|
||||
|**Additonal informaton(optonal)**|||
||||
||**SORP**<br>**reference**||
||Para 1.51|Through ordinary resoluton of the charity. The trustees<br>may appoint a person who is willing to act as a Trustee.|
|**Policies and procedures**<br>**adopted for the inducton**<br>**and training of trustees**|||
||Para 1.51|CIO by foundaton. The charity is governed by its board of<br>trustees and operated day to day by an unremunerated<br>Chief Executve Ofcer.<br>The charity works with academic partners including King’s<br>College London, the Vrije Universiteit Brussel and<br>Newcastle University.|
|**The charity’s**<br>**organisatonal structure**<br>**and any wider network**<br>**with which the charity**<br>**works**|||





**Relationship with any** Para 1.51 The Chief Executive Officer, Adrian Zacher, is the founder **related parties** and a director of Snorer.com Ltd, which owns the intellectual property in the SleepNav clinical decision support system. Mr Zacher is not a charity trustee and receives no remuneration or other benefit from the charity. eeZed Ltd, of which Mr Zacher’s spouse Emma Zacher is sole director, provides hosting, domain and web development support to the charity at subsidised rates with an estimated value of approximately £1,000 per annum. There is no written agreement governing this arrangement. These relationships are set out in full in board paper BSPSS/2026/GOV/001, Related Party Disclosure. During the period the charity sold Sunrise home sleep apnoea test devices to Wansford Health Ltd. Sefam Medical UK and Zoll Itamar provided unconditional **Other** grant funding. 

## **Reference and Administrative details** 

||The Britsh Society of Pharmacy Sleep Services|
|---|---|
|**Charity name**||
||BSPSS|
|**Other name the charity uses**||
||1198553|
|**Registered charity number**||
||4 Waterford Lane, Cherry Willingham, Lincoln, LN3 4AL|
|**Charity’s principal address**||



**Names of the charity trustees who manage the charity** 

||||||
|---|---|---|---|---|
||**Trustee name**|**Ofce (if any)**|**Dates acted if not for**|**Name of person or**<br>**body enttled to**<br>**appoint trustee (if**<br>**any)**|
||||**whole year**||
|1|ROD TUCKER|President||Founding trustees|
|2|EDWARD GRANDI|Treasurer||Founding trustees|
|3|ADRIAN WILLIAMS|Educaton||Board of Trustees|
|4|LOUISE BERGER|Educaton||Board of Trustees|





5 LOUISE ORGANISTA Maternity leave 22 July 2025 Board of Trustees 

**Corporate trustees: names of the directors at the date the report was approved** 

**Director name** Not applicable. The charity has no corporate trustee. 

**Name of trustees holding title to property belonging to the charity** 

**Trustee name** Not applicable. 

**Funds held as custodian trustees on behalf of others** 

Not applicable. 

**Names and addresses of advisers (optional information)** 

**Type of adviser** None. 

**Name of chief executive or names of senior staff members (optional information)** 


Adrian Zacher, Chief Executive Officer. The role is unremunerated and the Chief Executive Officer is not a charity trustee. 

**Exemptions from disclosure** 

Not applicable. **Reason for non-disclosure of key personnel details** 

**Other optional information** 

**Events after the end of the** In August 2026, after the end of the reporting period, three **reporting period** trustees resigned: Gareth Evans, who held the office of President, Raj Nutan and Lizzie Hill. In September 2026 Breege Leddy resigned. Dr Rod Tucker, a continuing trustee, was appointed President. The board comprises five trustees at the date of this report. 

**Declarations** 

The trustees declare that they have approved the trustees’ report above. 

**Signature(s) Full name(s)** Edward Grandi 



Treasurer **Position (eg Secretary, Chair, etc) Date** 22/09/2026 **Signed on behalf of the charity’s trustees** 



|**Charity Name**<br>**No (if any)**<br>**The British Society of Pharmacy Sleep Services**<br>**1198553**<br>**Receipts andpayments accounts**<br>Period start date<br>**To**<br>Period end date<br>1 December 2024<br>30 November 2025<br>**DRAFT for trustee consideration. Not approved. See Notes sheet.**<br>**For the period**<br>**from**|**Charity Name**<br>**No (if any)**<br>**The British Society of Pharmacy Sleep Services**<br>**1198553**<br>**Receipts andpayments accounts**<br>Period start date<br>**To**<br>Period end date<br>1 December 2024<br>30 November 2025<br>**DRAFT for trustee consideration. Not approved. See Notes sheet.**<br>**For the period**<br>**from**|**Charity Name**<br>**No (if any)**<br>**The British Society of Pharmacy Sleep Services**<br>**1198553**<br>**Receipts andpayments accounts**<br>Period start date<br>**To**<br>Period end date<br>1 December 2024<br>30 November 2025<br>**DRAFT for trustee consideration. Not approved. See Notes sheet.**<br>**For the period**<br>**from**|**Charity Name**<br>**No (if any)**<br>**The British Society of Pharmacy Sleep Services**<br>**1198553**<br>**Receipts andpayments accounts**<br>Period start date<br>**To**<br>Period end date<br>1 December 2024<br>30 November 2025<br>**DRAFT for trustee consideration. Not approved. See Notes sheet.**<br>**For the period**<br>**from**|**Charity Name**<br>**No (if any)**<br>**The British Society of Pharmacy Sleep Services**<br>**1198553**<br>**Receipts andpayments accounts**<br>Period start date<br>**To**<br>Period end date<br>1 December 2024<br>30 November 2025<br>**DRAFT for trustee consideration. Not approved. See Notes sheet.**<br>**For the period**<br>**from**|**Charity Name**<br>**No (if any)**<br>**The British Society of Pharmacy Sleep Services**<br>**1198553**<br>**Receipts andpayments accounts**<br>Period start date<br>**To**<br>Period end date<br>1 December 2024<br>30 November 2025<br>**DRAFT for trustee consideration. Not approved. See Notes sheet.**<br>**For the period**<br>**from**|**CC16a**|
|---|---|---|---|---|---|---|
||**For the period**<br>**from**|Period start date<br>1 December 2024|**To**||Period end date<br>30 November 2025||
||||||||
|**Section A Receipts and payments**|||||||
|**to the nearest      £**<br>**A1 Receipts**<br>Donations<br>**4**<br>Sponsorship<br>**500**<br>Charitable activities<br>**822**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**1,326**<br>**-**<br>**-**<br>**_Sub total_                               -**<br>**_Total receipts_                     1,326**<br>**A3 Payments**<br>Sleeptest devicespurchased for supply<br>**996**<br>Workshopfacilitation fees<br>**204**<br>Insurance<br>**274**<br>Regulatoryand statutoryfees<br>**95**<br>Website, software and subscriptions<br>**63**<br>Travel<br>**141**<br>Bank andpaymentprocessingcharges<br>**2**<br>**-**<br>**-**<br>**_Sub total_                        1,775**<br>**-**<br>**-**<br>**_Sub total_                                -**<br>**_Total payments_                     1,775**<br>**_Net of receipts/(payments)_ -                      449**<br>**A5 Transfers between funds**<br>**-**<br>**A6 Cash funds last year end**<br>**973**<br>**_Cash funds this year end_                        524**<br>**Unrestricted**<br>**funds**<br>~~**_Sub total(Gross income for_**~~<br>**_AR)_**<br>**A2 Asset and investment sales,**<br>**(see table).**<br>**A4 Asset and investment**<br>**purchases, (see table)**||**to the nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Restricted**<br>**funds**|**to the nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Endowment**<br>**funds**||**Total funds**<br>**to the nearest £**<br>**4**<br>**500**<br>**822**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**1,326**<br>**-**<br>**-**<br>**-**<br>**1,326**<br>**996**<br>**204**<br>**274**<br>**95**<br>**63**<br>**141**<br>**2**<br>**-**<br>**-**<br>**1,775**<br>**-**<br>**-**<br>**-**<br>**1,775**<br>**-                      449**<br>**-**<br>**973**<br>**524**|**Last year**<br>**to the nearest £**|
|||||||**-**|
|||||||**-**|
|||||||**-**|
|||||||**-**|
|||||||**-**|
|||||||**-**|
|||||||**-**|
|||||||**-**|
|||||||**-**|
||||||||
||||||||
|||||||**-**|
|||||||**-**|
||||||||
|||||||**-**|
||||||||
|||||||**-**|
|||||||**-**|
|||||||**-**|
|||||||**-**|
|||||||**-**|
|||||||**-**|
|||||||**-**|
|||||||**-**|
|||||||**-**|
|||||||**-**|
||||||||
||||||||
||||||||
|||||||**-**|
||||||||
|||||||**-**|
||||||||
|||**-**|**-**||**-                      449**|**-**|
|||**-**|**-**||**-**|**-**|
|||**-**|**-**||**973**|**-**|
|||**-**|**-**||**524**|**-**|





|**Section B Statement of assets and liabilities at the end of the period**|**Section B Statement of assets and liabilities at the end of the period**|**Section B Statement of assets and liabilities at the end of the period**||
|---|---|---|---|
|**Categories**<br>**B1 Cash funds**<br>**B2 Other monetary assets**<br>**B3 Investment assets**<br>**B5 Liabilities**<br>**B4 Assets retained for the**<br>**charity’s own use**<br>Signed by one or two trustees on<br>behalf of all the trustees|**Details**<br>NatWest business current account<br>**_Total cash funds_**<br>**Details**<br>**Details**<br>**Details**<br>**Details**<br>Signature<br>(agree balances with receipts and payments<br>account(s))|**to nearest £**<br>**to nearest £**<br>**524**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**524**<br>**-**<br>OK<br>OK<br>**to nearest £**<br>**to nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Cost (optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Cost (optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>Print Name<br>**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**Fund to which**<br>**asset belongs**<br>**Fund to which**<br>**asset belongs**<br>**Fund to which**<br>**liability relates**<br>**Amount due**<br>**(optional)**|**to nearest £**<br>**Endowment**<br>**funds**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||OK|
||||**to nearest £**<br>**Endowment**<br>**funds**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**Current value**<br>**(optional)**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**Current value**<br>**(optional)**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**When due**<br>**(optional)**|
|||||
|||||
|||||
|||||
|||||
|||||
||||Date of<br>approval|
|||||
|||||





**The British Society of Pharmacy Sleep Services Registered charity number 1198553** 

## **Notes to the receipts and payments accounts for the year ended 30 November 2025** 

## **Notes on preparation** 

1. Basis. The accounts are prepared on the receipts and payments (cash) basis, which is permitted for a non-company charity with gross income of GBP 250,000 or less. They are prepared from the NatWest business current account (sort code 51-70-15, account 85706701), which was the charity’s only bank account during the period. All funds are unrestricted. 

2. Gross presentation. Receipts collected through PayPal are shown at the amount paid by the donor or customer. PayPal fees of GBP 2.17 are shown within payments rather than netted against receipts. 

3. Receipts. Donations GBP 4.05, being one donation from a trustee. Sponsorship GBP 500.00 from ZOLL Medical UK. Charitable activities GBP 821.60, being Wansford Health Ltd GBP 771.60 and M Dobson GBP 50.00, for the supply of home sleep apnoea test devices and related services. 

4. Payments. Devices for supply GBP 996.00 (SEFAM Medical Ltd). Workshop facilitation GBP 204.00 (self-employed contractor, King’s College London workshops). Insurance GBP 274.36 (PolicyBee). Regulatory and statutory fees GBP 95.00 (Information Commissioner’s Office GBP 35.00 and Fundraising Regulator GBP 60.00). Website, software and subscriptions GBP 62.45 (Complianz GBP 52.00 and Paddle GBP 10.45). Travel GBP 140.96 (Trainline). Bank and payment processing charges GBP 2.17. 

5. Rounding. Actual receipts were GBP 1,325.65 and actual payments GBP 1,774.94. Individual lines are rounded to the nearest pound using the largest remainder method, so that the rounded figures reconcile exactly to the closing bank balance of GBP 523.91. The website, software and subscriptions line carries the rounding adjustment. 

6. Cut-off. A Trainline charge of GBP 127.97 incurred on 28 November 2025 was debited to the account on 1 December 2025 and therefore falls into the following financial year. 

7. Employees and trustees. The charity had no employees during the period and made no payments to trustees. The chief executive holds an unremunerated, non-trustee role. 

## **Matters requiring trustee decision before these accounts are approved** 

- D. Liabilities. Section B5 currently shows none. Confirm that no amounts were owed at 30 November 2025. 

